Sector News

Biotechnology company Relypsa explores potential sale-sources

April 8, 2016
Life sciences

Relypsa Inc, a U.S. maker of treatments for blood disorder hyperkalemia, is exploring a sale following a number of overtures from potential buyers, according to people familiar with the matter.

Relypsa is working with investment bank Centerview Partners Holdings LLC to review offers, the people said. The discussions are in their early stages and may not lead to a sale, the people added, asking not to be identified because the talks are private.

Interest in Relypsa has picked up in recent months after the $2.7 billion sale of ZS Pharma to AstraZeneca Plc, the people said. Relypsa and ZS Pharma are the primary competitors in a race to control the market for hyperkalemia treatment, which some estimates say could be worth more than $6 billion.

Several of the companies that unsuccessfully bid for ZS Pharma have reached out to Relypsa, the people said.

Relypsa declined to comment. Centerview did not respond to a request for comment.

By Carl O’Donnell

Source: Reuters

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”